SHM-D33 (ATCC® CRL-1668)

Organism: Homo sapiens; Mus musculus, human; mouse  /  Cell Type: B lymphoblast; somatic cell hybridoma  /  Tissue: heteromyeloma  / 

Permits and Restrictions

View Permits

Organism Homo sapiens; Mus musculus, human; mouse
Tissue heteromyeloma
Cell Type B lymphoblast; somatic cell hybridoma
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
This line was produced by fusing the human myeloma cell line FU-266, clone E-1 (HAT sensitive, 8-azaguanine resistant and resistant to G-418 - an antibiotic similar to gentamicin) with the murine myeloma P3X63Ag8.653 (see ATCC CRL-1580).
Comments Tested and found negative for ectromelia virus (mousepox).
Complete Growth Medium Modified Dulbecco's medium supplemented with 0.2 mg/ml G418 (Geneticin) and 20% fetal bovine serum
Subculturing
Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 to 4 x 104 viable cells/mL. Maintain cultures at a cell concentraton between 3 x 104 and 8 x 105 cells/mL.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Complete growth medium supplemented with 7.5% (v/v) DMSO
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C
Growth Conditions: The cells are grown in 200 to 400 mcg/mL of G-418 to maintain selection for the human chromosomes.
Population Doubling Time 36 hours
Name of Depositor HS Kaplan
References

Teng NN, et al. Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. Proc. Natl. Acad. Sci. USA 80: 7308-7312, 1983. PubMed: 6316357

Kearney JF, et al. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550, 1979. PubMed: 113458

Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745

Yamagishi S, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272: 8723-8730, 1997. PubMed: 9079706

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Teng NN, et al. Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. Proc. Natl. Acad. Sci. USA 80: 7308-7312, 1983. PubMed: 6316357

Kearney JF, et al. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123: 1548-1550, 1979. PubMed: 113458

Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745

Yamagishi S, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272: 8723-8730, 1997. PubMed: 9079706